Predictive Oncology Inc. Reports Q2 Earnings: Significant Losses Amid Financial Challenges
ByAinvest
Saturday, Aug 16, 2025 5:44 am ET1min read
POAI--
Key Financial Highlights:
- Consolidated revenue increased by 21.5% to $119.8 million.
- Gross profit rose by 34.4% to $17.5 million.
- Net loss decreased to $17.0 million compared to $15.5 million in Q2 2024.
- Basic and diluted earnings per share improved to $(0.15) from $(0.17).
- Adjusted EBITDA improved to $(4.1) million from $(8.7) million.
Operational Highlights:
- Fee-for-service revenue grew by 10%.
- Retail Pharmacy and Dispensary set fill records, contributing $62.6 million in revenue and over $11 million in gross profit.
- Expansion plans in Florida and Nevada are underway, with potential to double the number of lives covered under existing partnerships.
Outlook:
The Oncology Institute reaffirms its full-year 2025 guidance:
- Revenue: $460 to $480 million.
- Gross Profit: $73 to $82 million.
- Adjusted EBITDA: $(8) to $(17) million.
- Free Cash Flow: $(12) to $(21) million.
The company expects Adjusted EBITDA of approximately $(2.5) to $(3.5) million in the third quarter of 2025. Despite the positive outlook, the company acknowledges potential risks and uncertainties, including those related to tariff rate increases, exchange rate changes, and the impact of COVID-19.
References:
[1] https://www.morningstar.com/news/globe-newswire/9511976/the-oncology-institute-reports-second-quarter-2025-financial-results-and-reaffirms-full-year-2025-guidance
TOI--
Predictive Oncology reported a significant loss of $4.51 million in the first half of 2025, with total assets decreasing to $3.44 million. Revenue increased to $112,992, but operating expenses remained high, leading to continued losses. The company is facing financial challenges, including a stockholders' deficit of $1.65 million, and is actively exploring funding options to sustain operations and meet Nasdaq's listing requirements.
The Oncology Institute, Inc. (NASDAQ: TOI) reported its second-quarter 2025 financial results, showcasing robust revenue growth and a reaffirmation of its full-year guidance. The company's CEO, Daniel Virnich, highlighted the strong performance, particularly in the pharmacy business, which grew by over 40% year-over-year, and the addition of over 50,000 new capitated lives to its value-based business.Key Financial Highlights:
- Consolidated revenue increased by 21.5% to $119.8 million.
- Gross profit rose by 34.4% to $17.5 million.
- Net loss decreased to $17.0 million compared to $15.5 million in Q2 2024.
- Basic and diluted earnings per share improved to $(0.15) from $(0.17).
- Adjusted EBITDA improved to $(4.1) million from $(8.7) million.
Operational Highlights:
- Fee-for-service revenue grew by 10%.
- Retail Pharmacy and Dispensary set fill records, contributing $62.6 million in revenue and over $11 million in gross profit.
- Expansion plans in Florida and Nevada are underway, with potential to double the number of lives covered under existing partnerships.
Outlook:
The Oncology Institute reaffirms its full-year 2025 guidance:
- Revenue: $460 to $480 million.
- Gross Profit: $73 to $82 million.
- Adjusted EBITDA: $(8) to $(17) million.
- Free Cash Flow: $(12) to $(21) million.
The company expects Adjusted EBITDA of approximately $(2.5) to $(3.5) million in the third quarter of 2025. Despite the positive outlook, the company acknowledges potential risks and uncertainties, including those related to tariff rate increases, exchange rate changes, and the impact of COVID-19.
References:
[1] https://www.morningstar.com/news/globe-newswire/9511976/the-oncology-institute-reports-second-quarter-2025-financial-results-and-reaffirms-full-year-2025-guidance
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet